مواقع التدريسيينجامعة الكوفة
0Publications
0Lectures

About

educational attainment: Bachelors degree in pharmacy from Kufa university/ college of pharmacy in 2012 .
Master degree in pharmacology and toxicology from Babylon university/college of medicine in 2020
PhD in Pharmaceutical Sciences from the University of Kufa/College of Pharmacy in 2024
The work: trainee pharmacist in Morgan Medical City/ babylon from 2012-2014
tutor in pharmacognosy and medicinal plants department /Kufa university/college of pharmacy from 2014-2018
teacher assistant in pharmacognosy and medicinal plants department/kufa university/college of pharmacy from 2020

Publications

2
2020

Study of Some SNPs for PIK3CA Gene in Laryngeal Cancer Cells line (HEP-2)

Authors LUBNA SAMI ALI, NISREEN J. MOHAMMED, RANA A. GHALEB3,SHAIMAA A. AL-OUBAIDY
JournalInternational Journal of Pharmaceutical Research
Abstract

Mutations of the phosphatidyl-inositol 3-kinase (PI3k) Pathway in the head and neck squamous cell carcinoma ( HNSCC) may accelerate the malignant cells formation which is already genetically aberrant, resulting in further genomic aberrations in known cancer genes. The PI3KCA gene, which codes the catalytic subunit p110α, is one of the important mutated oncogenes found in human cancers and considered as a tool for diagnostic and therapeutic targets. The results of the sequence of PCR products of amplified gene PI3KCA in the hep2 cell line include three detected SNPs and were found to be previously known as rs138281424, rs1057519925, and rs751920344 for the detected G535A, G703A, and T606C, respectively. PIK3CA was a serious potential target for pathway-specific, kinase-inhibitor-based therapies in laryngeal cancer.

Cytotoxic Effect of Pioglitazone in Colorectal Cancer Cell Line SW480

AuthorsLubna Sami ALI , Ali M. JANABI
JournalLatin American Journal of Pharmacy
Abstract

Colorectal cancer has several etiologies. It ranks third in terms of cancer frequency and is the second leading cause of cancer-related deaths globally. Drug repurposing involves identifying new therapeutic applications for medicines that are already available. pioglitazone is a thiazolidinedione medication that aids in regulating elevated blood glucose levels by enhancing the body’s sensitivity to insulin. We tested the pioglitazone effect on colon cancer cell line by measuring caspase-3, CDH1, STAT3 gene expression, and COX2 protein level. This study used pioglitazone at various concentrations on SW480 cells. Cell proliferation was measured using MTT. The study also examined the effect of pioglitazone on caspase-3, CDH1, and STAT3 gene expression using quantitative real-time polymerase chain reaction. The Elisa technique measured cox2 protein. Cell proliferation tests showed the dose-dependent anticancer effects of pioglitazone. Pioglitazone upregulates caspase-3 and CDH1 gene expression with downregulation of STAT3 and decreases COX2 protein levels. Pioglitazone might be a promising option for studying colon cancer and developing anti-cancer medications. This medication has the potential to treat cancer because of its anti-inflammatory, antiproliferative, and antimetastatic characteristics.

Lectures

6
View details